Clinical Trial Update: Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study [Phase 4]

View source ↗

Summary

A Phase 4 pilot trial evaluating dolutegravir-lamivudine dual therapy in ART-naïve HIV-1 patients with M184V mutation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dolutegravir/Lamivudine (dolutegravir/lamivudine)

Snippet

Sponsor: Pedro Cahn | Conditions: HIV-1 Infection | Phase 4 | Status: WITHDRAWN